KDR and neoplasm: Brivanib stands out as a multi-targeted anti-tumor agent primarily targeting vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR), thereby impeding angiogenesis and tumor cell proliferation [47].